SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is actively debated following its earnings report, with many in the community citing substantial non-cash benefits to net income as evidence of "cooked books" and "fraud," intensifying discussions around its valuation and long-standing concerns about subprime lending and a challenging used car market.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma ($FIG) is trending following a strong Q4 earnings beat and optimistic revenue guidance, highlighted by its strategic partnership with Anthropic to integrate AI-generated code into its design platform. This news has sparked community optimism, with many believing AI will expand Figma's market rather than disrupt it, fueling discussions of a potential short squeeze and significant upside, despite ongoing skepticism regarding broader SaaS sector challenges.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing significant upward momentum following European regulatory approval for its bladder cancer drug ANKTIVA, fueling strong community discussion about a potential short squeeze given substantial short interest and active call option positions. Investors are also anticipating further global expansion and broader therapeutic indications, driving sustained buying pressure.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is experiencing intense volatility after its earnings report delivered a Q4 miss on top-line and bottom-line figures, alongside a weaker near-term profit outlook, despite strong full-year guidance and marketplace gross order volume. The community is sharply divided, with some celebrating a significant recovery and annual growth, while others point to valuation concerns and stiff competition in the food delivery sector.

Booking Holdings, Inc. engages in the provision of online travel and related solutions. The firm offers services through the following brands: Booking.com, Priceline, Agoda, KAYAK, and OpenTable. It provides accommodation reservations including hotels, hostels, apartments, vacation rentals, and other properties. The company was founded by Jay Scott Walker on July 18, 1997, and is headquartered in Norwalk, CT.

Booking Holdings Inc

Booking Holdings is trending following robust earnings that surpassed expectations and the significant announcement of a 25-for-1 stock split, sparking widespread community discussion about its potential impact and the continued strength of the travel sector.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following its strong earnings beat, robust guidance, and the strategic acquisition of Depop. The community is actively discussing management's savvy move to capture a younger demographic and highlighting the company's attractive valuation relative to its growth.

Etsy, Inc. engages in the operation of an online marketplace. It offers handmade products such as shoes, clothing, bags, and accessories. It operates through the following segments: Etsy, Reverb, and Depop. The company was founded in 2005 and is headquartered in New York, NY.

Etsy Inc

Etsy is trending as the community analyzes eBay's $1.2 billion cash acquisition of its Depop subsidiary; this cash infusion is seen by many as a boost for share repurchases and reinvestment, despite discussions around the initial acquisition loss.

Remitly Global, Inc. engages in the provision of digital financial services for immigrants and their families. The company was founded by Matthew B. Oppenheimer and Joshua Hug on October 3, 2018 and is headquartered in Seattle, WA.

Remitly Global Inc

Investors are actively discussing Remitly Global (RELY) ahead of its earnings report, with many expecting a significant post-release rally fueled by its strong digital money transfer growth and AI initiatives. However, some remain cautious, recalling a historical pattern of price drops despite positive past results, leading to a divided community sentiment.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is a major focal point ahead of its upcoming earnings report, with community discussion intensely focused on its elevated valuation and recent trillion-dollar market cap, as market participants debate its e-commerce expansion and AI integration versus concerns about it being an overextended defensive play.

B2Gold Corp. is an exploration company, which engages in the acquisition and development of mineral properties. It operates through the following segments: Fekola Mine, Fekola Regional, Masbate Mine, Otjikoto Mine, Goose Project, Other Mineral Properties, and Corporate and Other. The Fekola Regional segment consists of Bantako North, Menankoto, Dandoko, and Bakolobi properties. The Other Mineral Properties segment focuses on the company interests in mineral properties which are at various stages of exploration and evaluation. The Corporate and Other segment includes the corporate operations. The company was founded by Mark Anthony Corra, Thomas A. Garagan, Clive Thomas Johnson, and Roger Thomas Richer on November 30, 2006 and is headquartered in Vancouver, Canada.

B2gold Corp

B2Gold (BTG) is trending due to widespread anticipation of its upcoming earnings report, with the community actively debating the impact of strong gold prices and perceived undervaluation against ongoing concerns about operational execution and geopolitical stability impacting its mining permits.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company had previously said that it expects to submit an application for approval of the therapy in the first quarter of 2026.</li><li>In the December meeting with the FDA, the company discussed its clinical data and regulatory strategy.&nbsp;</li><li>In the second meeting, in January, it discussed chemistry, manufacturing, and controls (CMC) requirements.</li></ul>Shares of Spruce Biosciences, Inc. (SPRB) fell 8% on Wednesday after the company pushed back on its timeline to submit an application to the U.S. Food and Drug Administration seeking approval for its enzyme replacement therapy in patients with Sanfilippo Syndrome Type B.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260218269143/en/Spruce-Biosciences-Announces-Positive-Type-B-Meetings-with-U.S.-FDA-for-TA-ERT-for-the-Treatment-of-Sanfilippo-Syndrome-Type-B-MPS-IIIB">said</a> that it completed two meetings with the FDA regarding its planned upcoming biologics license application (BLA) submission for tralesinidase alfa enzyme replacement therapy (TA-ERT) in the treatment of Sanfilippo syndrome type B.While the first meeting was held in Dec. 2025, the second was held in Jan. 2026. In the December meeting, the company discussed its clinical data and regulatory strategy, while in the second meeting, it discussed chemistry, manufacturing, and controls (CMC) requirements.The company now anticipates making the submission for TA-ERT in the fourth quarter of 2026 to accommodate the clinical and other requirements flagged by the FDA in the meetings. Spruce Biosciences had previously said that it expects to submit an application for approval of the therapy in the first quarter of 2026.<h2 class="st-heading-2">About Sanfilippo syndrome type B</h2>Sanfilippo syndrome type B (MPS IIIB) is a rare, inherited lysosomal storage disease caused by a deficiency in the enzyme alpha-N-acetylglucosaminidase, leading to the accumulation of heparan sulfate in cells, particularly neurons. It causes progressive neurological symptoms like cognitive and developmental impairment, hyperactivity with aggressive and destructive behavior, delayed speech, hearing loss, and motor skill deficits.Tralesinidase Alfa Enzyme Replacement Therapy is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB.“While the timing of our submission is now expected in the fourth quarter of this year, we believe in the strength of our long-term data for TA-ERT which demonstrates that reductions in CSF HS-NRE are associated with meaningful clinical benefits across cognition, communication, and motor skill acquisition,” CEO Javier Szwarcberg said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SPRB stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/SPRB">SPRB stock</a> has gained nearly 372% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mbrx-stock-climb-today/cZR0CkIR4vA">Why Did MBRX Stock Climb 14% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ADIL’s stock has declined 75% over the past 12 months.

SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy 

Spruce Biosciences now anticipates making the submission for TA-ERT in the fourth quarter of 2026 to accommodate the clinical and other requirements flagged by the FDA in meetings.

Equity

Spruce Biosciences now anticipates making the submission for TA-ERT in the fourth quarter of 2026 to accommodate the clinical and other requirements flagged by the FDA in meetings.


Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Long-Term Data Presented at the 22nd Annual WORLDSymposium Highlights Tralesinidase Alfa Enzyme Replacement Therapys Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Consensus Rating of "Hold" from Brokerages

Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) have been given a consensus recommendation of "Hold" by the nine brokerages that are presently covering the stock, MarketBeat.com...

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences

Harbour BioMed exercises its warrant to buy Spruce Biosciences shares, raising its stake to about 3.8% as the companies work together on the SPR202 drug program.read more...

Harbour BioMed Exercises Warrant To Acquire Stake In Spruce Biosciences

(RTTNews) - Harbour BioMed announced that, through its wholly-owned subsidiary, it has exercised its warrant to acquire common stock in Spruce Biosciences Inc. (SPRB). As a result of this...

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration PR Newswire...

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet...

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $WMT earnings on Thursday?

SPRB
Spruce Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest SPRB News

SPRBSpruce Biosciences Inc